| Patents for A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838) |
|---|
| 01/03/2003 | WO2003000280A2 Abin-mediated hepatitis protection |
| 01/03/2003 | WO2003000274A2 Bacteriophage preparation for the treatment of intracellular bacterial infection |
| 01/03/2003 | WO2003000273A1 Modulating serum amyloid a interaction with tanis and agents useful for same |
| 01/03/2003 | WO2003000199A2 Ilt3 and ilt4-related compositions and methods |
| 01/03/2003 | WO2003000021A2 Pancam nucleic acids and polypeptides |
| 01/03/2003 | WO2002072754A9 Mva expressing modified hiv envelope, gag, and pol genes |
| 01/03/2003 | WO2002070594A3 A method of preparing a collagen sponge, a device for extracting a part of a collagen foam, and an elongated collagen sponge |
| 01/03/2003 | WO2002055676A3 Method for processing dendritic cells and for activating macrophages with ru 41740 |
| 01/03/2003 | WO2002044366A3 Retina-specific human proteins c70rf9, c120rf7, mpp4 and f379 |
| 01/03/2003 | WO2002044322A3 Bacteriophage composition useful in treating food products to prevent bacterial contamination |
| 01/03/2003 | WO2002043647A3 Oncolytic virus |
| 01/03/2003 | WO2002028891A3 Listeria inocua, genome and applications |
| 01/03/2003 | WO2002026209A3 Microparticles for delivery of the heterologous nucleic acids |
| 01/03/2003 | WO2002007759A3 Clostridial toxin derivatives and methods for treating pain |
| 01/03/2003 | WO2001098357A3 Compositions and methods of monoclonal and polyclonal antibodies specific for t cell subpopulations |
| 01/03/2003 | WO2001094549A9 Methods of differentiating and protecting cells by modulating the p38/mef2 pathway |
| 01/03/2003 | WO2001081551A8 Retinal pigment epithelial cell lines with extended life-span and their applications |
| 01/03/2003 | CA2459985A1 Pancam nucleic acids and polypeptides |
| 01/03/2003 | CA2451864A1 Methods of inducing a cytotoxic immune response and recombinant simian adenovirus compositions useful therein |
| 01/03/2003 | CA2451637A1 Liver engrafting cells, assays, and uses thereof |
| 01/03/2003 | CA2451486A1 Dopaminergic neurons and proliferation-competent precursor cells for treating parkinson's disease |
| 01/03/2003 | CA2451328A1 Novel human cytomegalovirus (hcmv) cytotoxic t cell epitopes, polyepitopes, compositions comprising same and diagnostic and prophylactic and therapeutic uses therefor |
| 01/03/2003 | CA2451271A1 Pancam nucleic acids and polypeptides |
| 01/03/2003 | CA2451250A1 Modulating serum amyloid a interaction with tanis and agents useful for same |
| 01/03/2003 | CA2447249A1 Abin-mediated hepatitis protection |
| 01/02/2003 | US20030004211 Carbohydrate modifying agent and drinks containing the modifying agent |
| 01/02/2003 | US20030004099 The use of copolymer 1 and related peptides and polypeptides and T cells treated therewith for neuroprotective therapy |
| 01/02/2003 | US20030004091 Medicinal combination useful for in vivo exogenic transfection and expression |
| 01/02/2003 | US20030003576 Peripheral blood fibrocytes differentiation pathway and migration to wound sites |
| 01/02/2003 | US20030003575 Apparatus for use in the generation of thin layered films |
| 01/02/2003 | US20030003574 Multipotent stem cells from peripheral tissues and uses thereof |
| 01/02/2003 | US20030003572 Propagation of preefrential nercous system tissue; obtain cells, inoculate nutrient broth containing nerve growth factor, propagate and recover cells |
| 01/02/2003 | US20030003447 Methods and compositions for modulating the interaction between the APJ receptor and the HIV virus |
| 01/02/2003 | US20030003169 Prepared by fermenting an aqueous Glycine max (L.) extract with at least one lactic acid bacteria together with at least one yeast |
| 01/02/2003 | US20030003159 Anticancer agents comprising powders of head and neck of soft-shelled turtle, bear gall, achyranthes root, bitter almond, black ant, rhubarb and muskiness |
| 01/02/2003 | US20030003158 Pharmaceutical composition for preventing and treating erectile impotence using purified sumsoo extract |
| 01/02/2003 | US20030003138 Articles with spores exhibiting antagonistic properties against pathogens and/or spores forming micro-organisms |
| 01/02/2003 | US20030003107 Topical compositions containing probiotic bacillus bacteria, spores, and extracellular products and uses thereof |
| 01/02/2003 | US20030003105 Comprising lecithin and a polymer, preferably polyacrylic acid |
| 01/02/2003 | US20030003098 Treating graft with molecule which binds to co-stimulatory protein of antigen-presenting cells |
| 01/02/2003 | US20030003090 Increasing the intracellular level of cyclic AMP; treating a human patient having a disease, condition, or disorder of the central nervous system |
| 01/02/2003 | US20030003089 Cells organized on a support to provide a three-dimensional cell structure; used for research or drug testing, in surgical implantation for the treatment of heart disease |
| 01/02/2003 | US20030003088 A human pancreatic ductal cell line immortalized with human papilloma virus genes E6 and E7 and which is capable of produce insulin; treating insulin-dependent diabetes; determining a chemical agent to induce cell differentiation |
| 01/02/2003 | US20030003086 A genetic engineered cell comprising an exogenously derived nucleic acid coding for a thimet oligopeptidase (TOP) polypeptide; modulate antigen presentation on cell surfaces, works synergistically with immunosuppressive drugs |
| 01/02/2003 | US20030003085 Drug delivery of a muscle protein by administering purified donor muscle side population cells; gene therapy, in the treatment muscle diseases muscular dystrophies, genetic diseases, treating cancer, and bone marrow transplant |
| 01/02/2003 | US20030003084 Human mesenchymal progenitor cell |
| 01/02/2003 | US20030003083 Administering a dose of non- alloreactive anti-third party cytotoxic T-lymphocytes (CTLs), which were generated by directing T-lymphocytes of the donor against a third party antigen or antigens |
| 01/02/2003 | US20030003082 Use of poly-Glu,Tyr and T cells treated therewith for neuroprotective therapy |
| 01/02/2003 | US20030003080 Reovirus for the treatment of cellular proliferative disorders |
| 01/02/2003 | US20030003079 Recombinant pox virus for immunization against tumor-associated antigens |
| 01/02/2003 | US20030003077 A genetic engineered adenoviral vector contains an adenoviral genome from which the open reading frames E1 and/or E3 were deleted and a therapeutic gene or a DNA sequence that encodes for therapeutic proteins useful in fibrosis treatment |
| 01/02/2003 | US20030003076 Adenovirus E1B-55K single amino acid mutants and methods of use |
| 01/02/2003 | US20030003059 For prophylaxis, therapy and/or management of dental and related tissue conditions, including dental caries, dental cavities, microbial flora, tartar, periodontal and related gum diseas |
| 01/02/2003 | EP1270719A2 Cell population containing non-fetal hemangioblasts and method for producing same |
| 01/02/2003 | EP1270599A1 Salmon-origin chondroitin sulfate |
| 01/02/2003 | EP1270009A1 Antiviral agent containing a combination of calcium salts of organic (fish and shells) and of mineral source |
| 01/02/2003 | EP1269988A1 Cosmetic or dermatological composition comprising acylaminoamide derivatives |
| 01/02/2003 | EP1269860A1 Pharmaceutical composition |
| 01/02/2003 | EP1269837A2 Allergen-containing milk for allergy treatment |
| 01/02/2003 | EP1268836A2 Novel sperm-dna complexes for genetically modifying non-human animals |
| 01/02/2003 | EP1268835A1 Retinoic acid receptor beta-2, its antagonists, and gene therapy vectors for the treatment of neurological disorders |
| 01/02/2003 | EP1268833A2 Modified nodavirus rna for gene delivery |
| 01/02/2003 | EP1268817A1 Human pyruvate dehydrogenese phosphatase |
| 01/02/2003 | EP1268812A2 Vectors for gene therapy |
| 01/02/2003 | EP1268802A2 Beta-like glycoprotein hormone polypeptide and heterodimer |
| 01/02/2003 | EP1268800A2 Mucin-1 specific binding members and methods of use thereof |
| 01/02/2003 | EP1268798A2 Anti-angiogenic and anti-tumor properties of vascostatin and other nidogen domains |
| 01/02/2003 | EP1268797A2 Compositions and methods for the therapy and diagnosis of lung cancer |
| 01/02/2003 | EP1268793A2 Fibroblast growth factor receptor-like molecules and uses thereof |
| 01/02/2003 | EP1268784A2 Genes involved in intestinal inflammatory diseases and use thereof |
| 01/02/2003 | EP1268783A2 Anti-angiogenic and anti-tumor properties of matin and other laminin domains |
| 01/02/2003 | EP1268764A2 Method for obtaining nucleic acids from an environment sample |
| 01/02/2003 | EP1268761A2 Human urothelial cell specific uroplakin transcriptional regulatory sequences, vectors comprising the same, and methods of use thereof |
| 01/02/2003 | EP1268746A2 PRODUCTION OF TcR GAMMA DELTA T CELLS |
| 01/02/2003 | EP1268542A2 Therapeutic anti-melanoma compounds |
| 01/02/2003 | EP1268536A1 Tcf responsive element |
| 01/02/2003 | EP1268529A2 Immuno-reactive peptide ctl epitopes of human cytomegalovirus |
| 01/02/2003 | EP1267954A1 Medical devices suitable for gene therapy regimens |
| 01/02/2003 | EP1267945A2 Compositions containing genetically modified lung cancer cells expressing a tgf-beta inhibitor |
| 01/02/2003 | EP1267944A1 Systemic gene delivery vehicles for the treatment of tumors |
| 01/02/2003 | EP1267931A1 Rhodamine derivatives for photodynamic diagnosis and treatment |
| 01/02/2003 | EP1267930A1 Cross-reactive displacing antibodies from collagen-binding proteins and method of identification and use |
| 01/02/2003 | EP1267924A2 Immunotherapeutic methods and compositions |
| 01/02/2003 | EP1267918A1 Method of treatment using ligand-immunogen conjugates |
| 01/02/2003 | EP1267914A1 Use of lyosomal acid lipase for treating atherosclerosis and related diseases |
| 01/02/2003 | EP1267898A2 Bile acid containing prodrugs with enhanced bioavailability |
| 01/02/2003 | EP1267897A1 Treatment of congestive heart failure by pretreated autologous blood |
| 01/02/2003 | EP1267837A1 Matrices containing nitric oxide donors and reducing agents and their use |
| 01/02/2003 | EP1267826A1 Pharmaceutical composition for treatment of mucosal epithelial ulceration and/or erosion |
| 01/02/2003 | EP1267616A1 Methods of modulating hair growth |
| 01/02/2003 | EP1210944A4 Blood plasma replacement solution |
| 01/02/2003 | EP0979284B1 Reagents for vaccination which generate a cd8 t cell immune response |
| 01/02/2003 | EP0930896B1 Method for tolerizing a mammalian patient to administration of gene therapy virus vectors |
| 01/02/2003 | EP0885007B1 Method for separating cells, especially platelets, and bag assembly therefor |
| 01/02/2003 | EP0863754B1 Hydrolysis-optimized lipid emulsions and use thereof |
| 01/02/2003 | EP0854725B1 Preparation of pharmaceutical grade hemoglobins by heat treatment in partially oxygenated form |
| 01/02/2003 | EP0806960B1 Extracts of shark cartilage, process of production and uses thereof |
| 01/02/2003 | EP0745131B1 Targeting gene therapy |
| 01/02/2003 | EP0628074B1 In vitro activation of cytotoxic t cells |
| 01/01/2003 | CN1388241A Making process of male moth and aspongopus wine |